Novo Nordisk A/S (NYSE:NVO) is one of the best depressed stocks to buy in 2025. On August 4, the company confirmed it had ...

Eli Lilly is one step closer to bringing an oral weight loss medicine to the booming obesity drug market. A clinical trial ...

In July 2025 alone, Wegovy clocked Rs 7 crore in sales with around 5,000 injections, while Mounjaro posted Rs 47 crore in ...

Lilly’s results from an obesity pill study didn’t perform as well as Wall Street expected. It resulted in lower weight loss ...

FRANKFURT: European shares logged their biggest daily rise in over two weeks on Thursday, boosted by financial ...

Analysts delivered mixed verdicts on Eli Lilly after the drugmaker released late-stage trial results for its investigational ...

In an 18-month clinical trial of the experimental GLP-1 pill orforglipron, about 60 percent of people lost at least 10 ...

EUROPEAN shares logged their biggest daily rise in over two weeks on Thursday, boosted by financial stocks as investors ...

Novo Nordisk's Canadian patent for weight loss drug Ozempic is set to expire in January 2026. Dr. Justin Ezekowitz discusses generic competitors that may come.

A series of lawsuits have been filed in Marion County court alleging that drug manufacturer Eli Lilly downplayed the side ...

Shares of Eli Lilly plunged after the drug maker reported less-than-stellar results of a new study of an experimental anti-obesity pill that is expected to become a blockbuster. The pill helped people ...

Shares of Eli Lilly & Co. suffered their biggest selloff in 26 years on Thursday, after the drug giant disclosed late-stage trial data for its weight-loss pill that fell well short of expectations.